Jonathan R. Keller, Ph.D.

Jonathan R. Keller, Ph.D.
Senior Investigator (Contr)
Head, Hematopoiesis and Stem Cell Biology Section

Dr. Jonathan Keller has a long standing interest in defining the molecular and cellular regulation of hematopoiesis. He characterized and purified interleukin 3, one of the first growth factors that regulate hematopoietic stem cell (HSC) development. He discovered that the proliferation of HSC is balanced by the action of negative growth regulators including transforming growth factor-β. His laboratory is currently focused on understanding how transcription factors regulate HSC quiescence, survival, self-renewal, and cell fate, and how they are integrated into wider transcription factor regulatory networks that regulate HSC development. It is anticipated that these studies will lead to the development of novel therapeutic agents, since transcription factors and their networks are frequently deregulated in hematopoietic malignancies.

Areas of Expertise
1) Stem Cell Biology 2) Hematopoiesis 3) Transcription Factors 4) Hematopoietic malignancies 5) Molecular regulation of self renewal and cell fate 6) Bone marrow transplantation

Contact Info

Jonathan R. Keller, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 560, Room 32-31D
Frederick, MD 27102-1201
Ph: 301-846-1461


Molecular Regulation of Hematopoietic Cell Growth/Differentiation

Hematopoiesis is a multi-stage developmental process that is maintained throughout life by a limited number of hematopoietic stem cells (HSC), which proliferate, self-renew, and differentiate into mature blood cells of all lineages. Central questions about the molecular regulation of HSC quiescence, self-renewal, and lineage commitment remain to be answered. These processes are tightly regulated by cell intrinsic mechanism(s), and extrinsic signals from cells in the hematopoietic microenvironment. Transcription factors are the ultimate downstream mediators of extrinsic signals received by the microenvironment, and cell intrinsic signals. Transcription factors, and the proteins/enzymes they recruit to DNA, regulate gene expression to promote HSC development. Since transcriptional regulators are frequently deregulated or mutated in hematopoietic malignancies, our current focus is to understand how transcription factors and transcription factor networks regulate quiescence, self-renewal and cell specification using mouse models, normal stem cells, and stem cell line models. We believe that knowledge of the molecular and cellular regulation of HSCs will contribute to improved methods to direct these processes to expand hematopoietic stem cells (HSCs), develop pharmaceuticals to treat leukemia and other hematological disorders, and improve methods of bone marrow transplantation (BMT), gene therapy, and regenerative medicine.

Inhibitors of DNA Binding (Id) Proteins in Normal Hematopoietic Development. Id proteins are members of the helix loop helix (HLH) family of proteins that function as dominant negative regulators of other basic HLH proteins, which regulate the differentiation and proliferation of muscle, neural, lymphoid and other cell lineages. We found that Id1 expression is induced by hematopoietic growth factors (HGF) including interleukin-3 (IL-3) to promote the proliferation of HSCs and their immediate progeny. Overexpression of Id1 in normal HSCs promotes myeloid differentiation, while inhibiting lymphoid development in vitro and in vivo. Thus, IL-3 may direct HSC fate via the induction of Id1 protein. Id1 immortalizes hematopoietic progenitors in vitro, promotes a myeloproliferative disease in vivo, and is widely expressed in human myeloid neoplasia, suggesting Id1 may contribute to the initiation or progression of hematopoietic malignancies. To define the physiological role of Id genes in normal hematopoietic development, we examined hematopoiesis in mice that lack Id1, Id2 and Id3. Since Id1 is induced in hematopoietic stem cells (HSCs) by proinflammatory cytokines that promote HSC proliferation and differentiation, we speculated that Id1 may function during stress hematopoiesis. Id1-/- HSCs show increased self-renewal in serial bone marrow transplantation (BMT) assays, which is correlated with decreased proliferation, decreased mitochondrial biogenesis, and decreased ROS production. Id1-/- HSCs harbor less DNA damage, show increased quiescence and reduced aging. Mechanistically, we show that cytokines and other proinflammatory stimuli present in the hematopoietic microenvironment after γ-irradiation induce Id1 expression. Id1-/- HSCs fail to properly respond to cytokine-induced proliferation, suggesting that HSC exhaustion is mediated, in part, by chronic proliferative stress. Id1-/- HSCs are protected from other chronic proliferative stresses including chronic genotoxic and inflammatory stress, and aging. Future studies are focused on evaluating if targeting Id1 may be therapeutically useful to improve normal mouse and human HSC survival and function during BMT, chronic stress and aging. 

We have discovered that Id1 and Id3 are required for the proper functioning of the hematopoietic microenvironment, and that loss of Id1 and Id3 expression in adult endothelial cells disrupts normal endothelial cell homeostasis resulting in dilated and hemorrhagic sinusoids, which leads to bone marrow failure. Current studies are focused on the molecular mechanism(s) by which Id genes regulate endothelial cell survival and proliferation. These studies leave open many questions including: Does Id1 regulate the development and/or function of other stromal cell lineages including mesenchymal stem/progenitor cells (MSC/MPC)? Is their differentiation affected by loss of Id1? What are the molecular mechanism(s) by which Id genes regulate microenvironmental function?

We found that Id2 is an intrinsic negative regulator of B cell development. Id2-/- mice show enhanced B cell development in the BM and spleen, while overexpression of Id2 inhibits B cell development by regulating E2A proteins. We also discovered that Id2 is a positive regulator of erythroid cell development. We demonstrated that Id2 regulates erythroid development by competing with GATA-1 for PU.1 binding, which relieves PU.1 mediated repression of GATA-1 activity, leading to enhanced expression of genes required for erythroid development. Based on these findings, we concluded that Id2 functions distinctly from Id1 in hematopoietic development, and intrinsically regulates lymphoid and erythroid cell fate via interaction with different target proteins, E2A and PU.1. Finally, we discovered that Id2 is a direct target of Gfi-1, and that Gfi-1 regulates B cell development by repressing Id2 gene expression. Since Id2 is highly expressed in normal HSCs, we hypothesized that Id2 may regulate normal HSC development.  We have discovered that Id2 is intrinsically required to maintain HSCs in mouse models of targeted deletion of Id2 in HSCs. Current studies are focused on defining the mechanism(s) by which Id2 maintains HSC quiescence and self-renewal, using advanced proteomics, single cell RNA-seq, Chip-Seq and ATAC-seq.

Id Genes and Leukemia, and Novel Transcriptional Regulators. Id genes are overexpressed in a broad range of cancers, suggesting that these proteins may represent therapeutic targets to treat cancer. We discovered that deregulated Id1 expression in HSC immortalizes BMCs and promotes a myeloid proliferative disease (MPD) in vivo. We found that Id1 and Id2 genes are overexpressed in AML cell lines and human AML patient samples, suggesting that deregulated expression of Id genes may contribute to the initiation and progression of AML. To test this, we plan to investigate if deregulated expression of Id2 and Id3 also contribute to MPD, lymphomas or AML, and investigate how Id genes immortalize murine HPC and contribute to MPD. We will also determine if Id genes are required for the survival and growth of human AML cell lines, and AML patient samples.

To identify novel transcriptional regulators of myeloid cell growth and differentiation, we have compared the global gene expression profile of undifferentiated and differentiating hematopoietic progenitor cells. We identified a novel zinc finger protein, pogo transposable element with zinc finger domain, Pogz, expressed in mouse and human stem cells, which is down regulated during the early stages of myeloid development. We have generated a mouse strain with a targeted deletion of Pogz. Pogz-/- mice do not survive beyond the first few hours of life, and die at birth of unknown causes, suggesting that Pogz is essential for mouse survival. Ablation of Pogz expression in adult hematopoietic cells in vivo results in persistence of embryonic β-like globin expression without significantly affecting erythroid development or mouse survival. Elevated embryonic β-like globin expression correlates with reduced expression of Bcl11a, a known repressor of embryonic β-like globin expression. Pogz binds to the Bcl11a promoter, and, to erythroid specific intragenic regulatory regions. Importantly, Pogz+/- mice show elevated embryonic β-like globin expression in peripheral blood cells, demonstrating that reducing Pogz levels can increase embryonic β-like globin expression. Finally, knockdown of Pogz in primary human CD34+ hematopoietic stem and progenitor cell derived erythroblasts, reduces Bcl11a expression and increases fetal hemoglobin expression. These findings are significant since new therapeutic targets and strategies are needed to treat the increasing global burden of β-globin disorders.  Future studies are focused on determining if Pogz binds DNA through a consensus sequence found in relevant promoters, and the role of Pogz in the development of hematopoietic stem and progenitor cells, and other hematopoietic cell lineages.




Scientific Focus Areas:
Cancer Biology, Cell Biology, Molecular Biology and Biochemistry, Stem Cell Biology
  1. Baba M, Toyama H, Sun L, Takubo K, Suh HC, Hasumi H, Nakamura-Ishizu A, Hasumi Y, Klarmann KD, Nakagata N, Schmidt LS, Linehan WM, Suda T, Keller JR.
    Stem cells . 34(4): 1068-82, 2016. [ Journal Article ]
  2. Kim W, Klarmann KD, Keller JR
    Blood. 124(10): 1586-96, 2014. [ Journal Article ]
  3. Satyanarayana A, Klarmann KD, Gavrilova O, Keller JR
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 26(1): 309-23, 2012. [ Journal Article ]
  4. Li H, Ji M, Klarmann KD, Keller JR
    Blood. 116(7): 1060-9, 2010. [ Journal Article ]
  5. Suh HC, Leeanansaksiri W, Ji M, Klarmann KD, Renn K, Gooya J, Smith D, McNiece I, Lugthart S, Valk PJ, Delwel R, Keller JR
    Oncogene. 27(42): 5612-23, 2008. [ Journal Article ]

Dr. Jonathan Keller obtained his Ph.D. under the direction of James Ihle at George Washington University, where he characterized and purified interleukin 3. He has a longstanding interest in the molecular and cellular regulation of hematopoietic cell growth and differentiation.

Name Position
Brad Jakubison Ph.D. Postdoctoral Fellow (Contr)
Kimberly D. Klarmann Ph.D. Scientist II (Leidos)
Shweta Singh Ph.D. Postdoctoral Fellow (Visiting)